WHO ICTRP trial
A Single Ascending Doses (SAD) of a Novel Engineered Cationic Peptide PLG0206 in…
ACTRN12618001920280 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12618001920280 |
|---|---|
| Public title | A Single Ascending Doses (SAD) of a Novel Engineered Cationic Peptide PLG0206 in Healthy Subjects. |
| Scientific title | Safety and Tolerability of Single Ascending Doses (SAD) of a Novel Engineered Cationic Peptide PLG0206 in Healthy Subjects |
| Primary sponsor | Peptilogics, Inc. |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | Australia |
| Conditions | Microbial Infections; Microbial Infections;Infection - Other infectious diseases |
| Interventions | Dose: Proposed dose escalation scheme 0.05, 0.125, 0.25, 0.5, 1, 2, and 3 mg/kg. Route of Administration: Intravenous infusion over 1 hour. There will be a minimum of 7 days between dose escalation within which the safety data will be… |
| Registration date | Nov 26, 2018 |
| Target size | 56 |
| Secondary IDs | 018-001 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: